Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Zapping the brain: can tDCS rewire schizophrenia?

NCT ID NCT05435300

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 28, 2026 · Updated 3 times

Summary

This study looks at whether a gentle brain stimulation technique called tDCS can change the density of synapses (connections between brain cells) in people with schizophrenia. Researchers will use special PET scans to measure these changes in 20 participants. The goal is to understand how tDCS works in the brain, not to treat symptoms directly.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcranial direct current stimulation (tDCS)
What this could lead to
If successful, this could reveal how tDCS affects brain connections, pointing toward better treatments for schizophrenia.
What could go wrong
This is a very small, early study (20 people) focused on measuring brain changes, not on treating symptoms. Results may not lead to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2021

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will have Schizophrenia/Schizoaffective Disorder and currently enrolled in the tDCS-adherence parent study (REB# 103-2018).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Enrolment in the tDCS-adherence parent study (REB# 103-2018). The parent study inclusion criteria are: 1. Male or female participants of any race or ethnicity 2. Inpatients or outpatients ≥18 years of age 3. DSM-V diagnosis of schizophrenia or schizoaffective disorder 4. Capable of consenting to participate in the research study 5. On a stable dose of oral antipsychotic drug and other concomitant medications for at least 2 months, and unlikely to undergo changes in dose during the study. Exclusion Criteria: The exclusion criteria for this study will be the same as the parent study (REB 103-2018). The parent study exclusion criteria are: 1. Unwilling or incapable to consent to the study based on the MacArthur Test of Competence 2. Unstable medical or any concomitant major medical or neurological illness, including a history of seizures 3. Acute suicidal or homicidal ideation 4. Formal thought disorder rating ≥3 on the Positive and Negative Syndrome Scale (PANSS) P2 conceptual disorganization item 5. DSM-V substance dependence (except caffeine, nicotine, and cannabis/marijuana) within 1 month of entering the study 6. Positive urine drug screen except for cannabis/marijuana at the screening visit 7. Metal implants or pacemaker precluding an MRI scan or other contraindications to MRI (e.g., claustrophobia) 8. Pregnancy 9. Score \<32 on the Wide Range Achievement Test-III Additional exclusion criteria for this companion study are: 1. Unwilling or incapable to consent to the study based on the MacArthur Test of Competence 2. Exposure to long-acting injectable antipsychotics in the last 6 months 3. Exceeding allowed annual radiation exposure levels (20 mSv), as outlined by our PET Centre guidelines 4. Receiving treatment with medications such as levetiracetam that blocks SV2a binding 5. Disorders of coagulation or taking anticoagulant medication 6. Having completed multiple PET scans in the past, such that participation in this study would cause participant to exceed lifetime limit (8 PET scans)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Schizoaffective are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre for Addiction and Mental Health

    Toronto, Ontario, M5T 1R8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.